Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.74 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.58 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.58 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 5/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 2/20 | 0.51 |
| ▸ | ROS1 | P08922 | 3/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1707837 | 0.99 | IGF1R (0.73) | IGF1RALKCDK19GLO1EGFR | |
| SCHEMBL9911244 | 0.87 | EGFR (0.57) | IGF1RALKGLO1EGFRPTGS1 | |
| SCHEMBL11342607 | 0.86 | IGF1R (1.00) | IGF1RALKCDK19LRRK2 | |
| SCHEMBL9911240 | 0.86 | EGFR (0.56) | IGF1RALKGLO1EGFRMET | |
| SCHEMBL9911237 | 0.86 | GLO1 (0.60) | IGF1RALKGLO1EGFRLRRK2 | |
| Hydrochloric Acid SCHEMBL1706872 | 0.86 | EGFR (0.56) | IGF1RALKGLO1EGFRPTGS1 | |
| SCHEMBL12726459 | 0.86 | CDK1 (0.65) | IGF1RALKCDK19GLO1EGFR | |
| Hydrochloric Acid SCHEMBL1707517 | 0.85 | EGFR (0.55) | IGF1RALKGLO1EGFRMET | |
| Hydrochloric Acid SCHEMBL1706957 | 0.85 | GLO1 (0.59) | IGF1RALKGLO1EGFRLRRK2 | |
| SCHEMBL9911239 | 0.85 | EGFR (0.58) | IGF1RALKGLO1EGFRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | ZAP70, LCK, DPY30 | IGF1R 3176/4885ALK 2709/4885CDK19 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.